scholarly journals Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-κB in A2A adenosine receptor induction

2005 ◽  
Vol 391 (3) ◽  
pp. 575-580 ◽  
Author(s):  
Lauren J. Murphree ◽  
Gail W. Sullivan ◽  
Melissa A. Marshall ◽  
Joel Linden

The A2A adenosine receptor (A2AAR) mediates anti-inflammatory actions of adenosine in a variety of cell types. LPS (lipopolysaccharide) was reported to induce a small (<2-fold) increase in the expression of A2AAR mRNA in human monocytes and monocytic cell lines. We investigated the effects of LPS on the expression of adenosine receptor mRNAs in primary mouse IPMΦ (intraperitoneal macrophages), human macrophages and Wehi-3 cells. Treatment with 10 ng/ml LPS for 4 h produced a >100-fold increase in A2AAR mRNA. LPS-induced increases in mRNA for A2AAR and TNFα (tumour necrosis factor α) are reduced by 90% in IPMΦ pretreated with the NF-κB (nuclear factor κB) inhibitor, BAY 11-7082 {(E)3-[(4-methylphenyl)sulphonyl]-2-propenenitrile; 10 μM}. In Wehi-3 cells exposed to LPS, A2AAR and A2BAR transcripts are elevated by 290- and 10-fold respectively, the A1AR transcript is unchanged and the A3AR transcript is decreased by 67%. The induction of A2AAR mRNA by LPS is detectable after 1 h, reaches a peak at 6 h at 600 times control and remains elevated beyond 24 h. The ED50 (effective dose) of LPS is 2.3 ng/ml. A2AAR receptor number, measured by 125I-ZM241385 binding to whole cells, is undetectable in naïve cells and increases linearly at a rate of 23 receptors·cell−1·min−1 to a Bmax of 348 fmol/mg (28000 receptors/cell) in 20 h. The increase in receptor number is correlated with an increase in the potency of an A2A agonist (4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester; referred to as ATL146e) to stimulate cAMP in these cells. After LPS pretreatment, the potency of the A2A agonist, ATL146e, to reduce TNFα release from IPMΦ was increased by 200-fold. The results support the hypothesis that regulation of adenosine receptor expression, especially up-regulation of the A2AAR, is part of a delayed feedback mechanism initiated through NF-κB to terminate the activation of human and mouse macrophages.

2006 ◽  
Vol 54 (8) ◽  
pp. 473-477 ◽  
Author(s):  
Philippe Giaime ◽  
Louis Carrega ◽  
Emmanuel Fenouillet ◽  
Laurence Mercier ◽  
Victoria Gerolami ◽  
...  

1998 ◽  
Vol 53 (4) ◽  
pp. 663-669 ◽  
Author(s):  
Zhongzhen Nie ◽  
Yun Mei ◽  
Mary Ford ◽  
Leonard Rybak ◽  
Adrianna Marcuzzi ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (5) ◽  
pp. 8738-8751 ◽  
Author(s):  
Yusuke Inoue ◽  
Katsuhiro Yoshimura ◽  
Nobuya Kurabe ◽  
Tomoaki Kahyo ◽  
Akikazu Kawase ◽  
...  

2005 ◽  
Vol 11 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Pier leopoldo Capecchi ◽  
Alessandra Camurri ◽  
Gerarda Pompella ◽  
Alessia Mazzola ◽  
Massimo Maccherini ◽  
...  

2007 ◽  
Vol 204 (7) ◽  
pp. 1559-1569 ◽  
Author(s):  
Zachary J. Roberts ◽  
Nadege Goutagny ◽  
Pin-Yu Perera ◽  
Hiroki Kato ◽  
Himanshu Kumar ◽  
...  

Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of action is unknown despite extensive preclinical and clinical investigations. Our data demonstrate that DMXAA is a novel and specific activator of the TANK-binding kinase 1 (TBK1)–interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway. DMXAA treatment of primary mouse macrophages resulted in robust IRF-3 activation and ∼750-fold increase in IFN-β mRNA, and in contrast to the potent Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein kinase (MAPK) activation and elicited minimal nuclear factor κB–dependent gene expression. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and IRF-3 but was myeloid differentiation factor 88–, Toll–interleukin 1 receptor domain–containing adaptor inducing IFN-β–, IFN promoter-stimulator 1–, and inhibitor of κB kinase–independent, thus excluding all known TLRs and cytosolic helicase receptors. DMXAA pretreatment of mouse macrophages induced a state of tolerance to LPS and vice versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-β expression were inhibited by salicylic acid. These findings detail a novel pathway for TBK1-mediated IRF-3 activation and provide new insights into the mechanism of this new class of chemotherapeutic drugs.


2007 ◽  
Vol 22 (3) ◽  
pp. 851-856 ◽  
Author(s):  
L. Carrega ◽  
E. Fenouillet ◽  
P. Giaime ◽  
A. Charavil ◽  
L. Mercier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document